Efectividad Absoluta del Nebivolol Asociado a Terapia Estándar en Pacientes con Insuficiencia Cardiaca Clase Funcional II o III

Abstract

SUMMARY Objective. The objective of this investigation, was to demonstrate the effectiveness of the use of the Nebivolol a betablocker drug of third generation and of recent appearance in our country, in patients with heart failure in functional class II or III according to the NYHA(1), in the improvement of clinical symptoms of the functional class. Material and Methods. The variables used in this study were, the heart and breathing rate, blood pressure, signs of heart congestion, tolerance to the exercise and the NYHA functional class (1), which were evaluated in the 7 days of the beginning the therapy and then every 14 days up to the 60 days with a control on day ninety. Results. The results were favorable in the 12 patients studied, being observed improvement in the tolerance to exercise and of the functional class in a progressive way. The majority of the patients presented improvement of the functional class and of the signs of heart failure from day 45 of the study, with a final percentage of patient in functional class I of 58,3% on days 60 and 90, out of 100% of patient in functional class III at the beginning of the study, concluding with a dosage of 5 mg per day of Nebivolol. Conclusions. It was concluded that the Nebivolol is an adrenergic-betablocker drug with excellent tolerance and with favorable results of the clinical variables of the heart failure.